Todos Medical Completes Installation of Lab Automation Equipment at Wisconsin Lab Client to Support COVID-19 PCR Testing

▴ Todos Medical Completes Installation of Lab Automation Equipment at Wisconsin Lab Client to Support COVID-19 PCR Testing
Todos Medical today announced that it has completed the installation of Tecan® laboratory automated equipment at its Wisconsin laboratory client, bringing the client’s total capacity to 12,000 COVID-19 PCR tests per day.

Todos Medical an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced that it has completed the installation of Tecan® laboratory automated equipment at its Wisconsin laboratory client, bringing the client’s total capacity to 12,000 COVID-19 PCR tests per day.

The installation and scripting of new Tecan EVO200 and Tecan Fluent 780 systems, in combination with the use of Todos’ proprietary ANDis 350 automated RNA extraction systems, allow the lab to process 12,000 PCR COVID-19 tests per day. The Company will continue to work with the client to further optimize the workflow to increase capacity to 18,000 tests per day in the weeks ahead and add additional automated liquid handling, extraction, and qPCR instrumentation as required to further support the client’s growth.

Provided that the client can continue to increase demand from its main client, the State of Wisconsin, the lab expects demand for Todos’ testing reagents and consumables to increase to 50,000 COVID-19 PCR tests per day in the next 6 weeks.

Concurrent with this announcement, the Company announced that it has secured a proprietary supply chain for the most in-demand lab consumable products required to conduct PCR testing. This supply chain allows Todos to source over 2,000,000 manual and robotic pipette tips per week for its clients, as well as PCR plates, providing a key competitive advantage to its clients over other labs. An international shortage of lab consumables has emerged as the key rate-limiting steps for laboratories to increase their PCR testing capacity worldwide.

“We are excited to have completed this installation process of the Tecan instruments in such a way that we can now replicate this process for several of our clients who are looking to further increase their capacity,” said Gerald Commissiong, President & CEO of Todos Medical. “Now that we have also secured access to sufficient lab consumables to allow our clients to grow unimpeded as compared with their competition, we are becoming laser-focused on supporting the further scaling up of our client’s operations within the lab to meet the surging demand for COVID-19 PCR testing in the state of Wisconsin.

Additionally, we have delivered a similar set of equipment, including Tecan liquid handlers, ANDis automated extraction, and PCR machines to one of our clients in Brooklyn that will allow it to reach similar COVID-19 testing capacities as our Wisconsin client, and we are working with them to implement the workflow in their lab. We expect revenues from our Wisconsin client to increase in the weeks ahead and expect that revenue from our client in Brooklyn to come online in December. We are very excited about the progress we are making in our base PCR lab testing business.”

About Todos Medical Ltd.

Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the third quarter of 2020.

Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle.

It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Additionally, Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Todos has formed strategic partnerships with Integrated Health LLC, MOTOPARA Foundation to deploy mobile COVID-19 testing in the United States.

Tags : #TodosMedical #TecanLabratory #WsconsinLabratory #Covid19ScreeningandDiagnosis #Covid19PCRTests #Covid19 #MOTOPARA #UnitedStates

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

ISB DLabs in collaboration with CitiusTech launches ‘I-HEAL @ ISB 3.0’: Accelerating Digital Healthcare Innovation in IndiaDecember 10, 2024
Aditya Roy Kapur unveils PartySmart Gummies for hangover preventionDecember 10, 2024
Sightsavers India and Alcon India Inaugurate Block Resource Centre aimed to Empower Children with Visual Impairment in BankuraDecember 10, 2024
Does Music Really Change Your Memories? The Answer Will Surprise YouDecember 10, 2024
NRAI cautions restaurants about the dangers of aggregator payment gateways and deep discounting on diningDecember 09, 2024
Hot Cocoa: A Surprising Ally in Fighting Stress and Boosting Heart HealthDecember 09, 2024
What Your Headache Says About Your Health And Why It Can Be More Than Just a Temporary PainDecember 09, 2024
Hot Cocoa: A Surprising Ally in Fighting Stress and Boosting Heart HealthDecember 09, 2024
Is Your Favorite Snack a Secret Weapon Against Diabetes?December 07, 2024
Is the Fountain of Youth Hidden in Your Cells? Discover the Future of Ageing With Indian AIDecember 07, 2024
Does Your Heart Have a Mind of Its Own? Science Says Yes!December 07, 2024
Does Your Heart Have a Mind of Its Own? Science Says Yes!December 07, 2024
Heart Risks Are Shrinking Men’s Brains: What Science Reveals About Gender and AgingDecember 06, 2024
P&G India Celebrates 20 Years of P&G Shiksha with its largest ever Employee Volunteer Day Initiative across all offices and sitesDecember 06, 2024
Air India SATS Scales up Green Initiative with AeroWash Now Serving Two of India's Busiest AirportsDecember 06, 2024
The Silent Culprit Behind Osteoarthritis: Are Ultra-Processed Foods Eating Away our BonesDecember 06, 2024
From Daily Pills to 2 Shots Per Year: The Future of HIV ProtectionDecember 06, 2024
BREAKTHROUGH CLINICAL STUDY, FIRST OF ITS KIND, PROVES TRAYA CUSTOMIZED REGIMEN DELIVERS 3X* BETTER RESULTS THAN THE MOST PRESCRIBED HAIR GROWTH SERUM December 06, 2024
The Airborne Mutation: Is Bird Flu Becoming a Human Threat? December 05, 2024
Aster CMI Hospital collaborate with Government of Arunachal Pradesh Provide Affordable Liver Transplantation Services.December 05, 2024